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Abstract
The aim of this study was to examine postnatal islet and beta-cell expansion in healthy female control mice and its
disturbances in diabetic GIPRdn transgenic mice, which exhibit an early reduction of beta-cell mass. Pancreata of female
control and GIPRdn transgenic mice, aged 10, 45, 90 and 180 days were examined, using state-of-the-art quantitative-
stereological methods. Total islet and beta-cell volumes, as well as their absolute numbers increased significantly until 90
days in control mice, and remained stable thereafter. The mean islet volumes of controls also increased slightly but
significantly between 10 and 45 days of age, and then remained stable until 180 days. The total volume of isolated beta-
cells, an indicator of islet neogenesis, and the number of proliferating (BrdU-positive) islet cells were highest in 10-day-old
controls and declined significantly between 10 and 45 days. In GIPRdn transgenic mice, the numbers of islets and beta-cells
were significantly reduced from 10 days of age onwards vs. controls, and no postnatal expansion of total islet and beta-cell
volumes occurred due to a reduction in islet neogenesis whereas early islet-cell proliferation and apoptosis were unchanged
as compared to control mice. Insulin secretion in response to pharmacological doses of GIP was preserved in GIPRdn
transgenic mice, and serum insulin to pancreatic insulin content in response to GLP-1 and arginine was significantly higher
in GIPRdn transgenic mice vs. controls. We could show that the increase in islet number is mainly responsible for expansion
of islet and beta-cell mass in healthy control mice. GIPRdn transgenic mice show a disturbed expansion of the endocrine
pancreas, due to perturbed islet neogenesis.
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Introduction
The functional pancreatic beta-cell mass is critical for adequate
insulin secretion, and therefore maintenance of glucose homeo-
stasis. Beta-cell mass is dynamic throughout life and may adapt to
meet the actual demand [1]. It is generally believed that neog-
enesis is the major driving process in the perinatal and in the early
postnatal period to rapidly expand beta-cell mass, whereas self-
replication is thought to contribute mainly to the slow expansion of
islet and beta-cell mass in later stages of postnatal pancreas
development under physiological conditions [2]. There are some
conflicting data in literature about the dynamics of numbers and
mean volumes of islets and beta-cells, but it seems generally
believed that islet number is fixed in postnatal life, whereas mean
islet size is thought to increase (islet hypertrophy) with age or
increasing demand [2,3,4,5]. Beta-cell mass is thought to increase
via both beta-cell hyperplasia and hypertrophy [1]. Changes in
islet size may be important considering functionality (cell-cell
interactions, blood supply) [5,6]. The aims of this study were to
analyze the postnatal development of total numbers and mean
volumes of islets and beta-cells of female control mice (CD1
outbred genetic background), and to determine the morphological
features of disrupted postnatal beta-cell mass expansion of diabetic
mice, expressing a dominant negative glucose-dependent insuli-
notropic polypeptide receptor (GIPRdn), using unbiased quantita-
tive-stereological methods.
GIP is an incretin hormone, which is released into the blood
stream from enteroendocrine cells after food intake, and produces
multiple physiological effects, including enhancement of glucose-
mediated insulin secretion and insulin gene transcription, and may
act as a mitotic and anti-apoptotic factor in pancreatic beta-cells
[7,8,9,10,11].
Previously, we have described a transgenic diabetic mouse
model, expressing a dominant negative GIP receptor in pancreatic
beta cells [12]. The cDNA of the human GIPR was mutated at the
third intracellular loop (deletion of amino acids 319–326,
AlaRGlu exchange at position 340). The loss of function of the
mutated GIPR was demonstrated in vitro. Transgenic mice were
then generated, expressing the mutated human GIPR cDNA under
the control of the rat pro-insulin 2 gene promoter in pancreatic
beta cells. These GIPRdn transgenic mice exhibit an early
disturbance in pancreatic islet development (severe reduction of
beta-cell mass, disturbed composition of islets with alpha-, delta-
and PP-cell hyperplasia and decreased islet neogenesis), dimin-
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ished insulin secretion, hyperglucagonemia and early onset
diabetes mellitus. The reduction in beta-cell mass precedes
development of hyperglycemia and is therefore thought to result
from transgene expression [12].
Materials and Methods
Animals
All animal experiments were performed according to the
German Animal Welfare Act with permission of the responsible
animal welfare authority (Regierung von Oberbayern, approval
ID 55.2-1-54-2531.2-26-06 and 94-07). Transgenic mice were
generated as previously described [12]. Transgenic males were
bred onto a CD1 background (Charles River, Germany). DNA
was extracted from tail tips as previously described, and transgenic
mice were identified by polymerase chain reaction [12]. Since our
previous investigations [12] revealed no difference in the
development of total islet and beta-cell volumes between male
and female control mice and since the phenotype of GIPRdn
transgenic mice is not influenced by gender, one gender (female)
was chosen for analyses.
Mice were maintained on a 12-h light and 12-h dark cycle and
received a standard breeding diet (C1314, Altromin, Germany)
and tap water ad libitum.
In vivo investigations
Blood was withdrawn from randomly fed mice at 10 days of age,
and at 45, 90 and 180 days of age after a 15-hour fasting period,
and following 1.5 hours re-feeding. Blood glucose was measured,
using the Super GLeasy System (Dr. Mu¨ller Gera¨tebau, Germany),
serum insulin and malondialdehyde were determined, using the
sensitive Rat Insulin RIA kit (Linco Research, USA) or the
TBARS Assay kit (Cayman Chemical Company, USA), respec-
tively.
At the age of 50 days, an insulin sensitivity test was carried out
with randomly fed mice. At the beginning, a basal blood sample
was taken from the nicked tail tip to determine blood glucose (t = 0
minutes). Thereafter, 1U insulin /kg body weight was injected
intraperitoneally. Further blood samples were obtained at 10, 20,
30 and 60 minutes for determination of blood glucose (Super
GLeasy System), and the relative decrease from basal blood glucose
levels was determined.
Glucose, GIP, and GLP-1 stimulation tests were performed at
10 days of age with randomly fed animals as described previously
[13], using 1.5 mg/kg body weight glucose and 1.5 mg/kg glucose
with either 1.7 mg/kg GIP or GLP-1 (Bachem, Germany).
Arginine stimulation tests were performed at 10 days of age,
using 1 mg/g body weight arginine in 0.9% NaCl. Animals were
euthanized 10 min after application of secretagogues or randomly
fed (basal values) by bleeding from the retroorbital plexus under
anesthesia, the pancreas was removed and insulin was extracted
using 0.18 M HCl in 95% alcohol over night. Blood glucose was
determined as described above, serum insulin and pancreatic
insulin content was determined, using the Ultra Sensitive Mouse
Insulin ELISA kit (Chrystal Chem Inc, USA). The increase in
insulin secretion from basal was calculated dividing insulin
concentrations after stimulation by mean basal levels (fold insulin
secretion) or by the pancreatic insulin content (relative secretion).
Isolated islets
Pancreatic islets were isolated at 10 days of age after neutral red
perfusion via the left heart ventricle and digestion of the pancreas
with collagenase Type I (Sigma, Germany) by handpicking under
a stereomicroscope. For determination of the cAMP content,
batches of 10–15 islets were boiled in 0.05 M HCl for 3 min, dried
by vacuum centrifugation (Vacuum concentrator, Bachofer,
Germany), resuspended in working buffer (Biomedical Technol-
ogies Inc., USA) and subjected to cAMP EIA (Biomedical
Technologies Inc.).
Immunohistochemistry
The indirect immunoperoxidase method was used to determine
insulin containing cells as described previously [12], as well as
BrdU-positive (Oxford Biotechnology, Great Britain), and apo-
ptotic cells (TUNEL, MP Biomedicals, France) on paraffin
embedded pancreatic tissue. Horseradish-conjugated rabbit anti-
guinea pig IgG, and rabbit anti-rat IgG were from DAKO
Diagnostika (Germany). The horseradish peroxidase labeled
streptavidin biotin method was used to localize insulin containing
cells in plastic embedded tissue, using the same guinea pig anti-
insulin antibody, but diluted 1:50 in phosphate buffered saline
(PBS). A biotinylated pig anti-rabbit IgG (1:50, Dako), which is
known to cross-react with guinea pig Ig, was used as secondary
antibody.
Quantitative-stereological investigations of the pancreas
Blood was collected from the tail vein to determine fasting blood
glucose levels and 1 ml/100 g body weight of a 10 mM BrdU
solution was injected intraperitoneally. Pancreas preparation was
performed as described previously [12,14] with some modifica-
tions. After fixation in 10% neutral buffered formalin, the
pancreas was embedded in agar, sectioned perpendicular to its
longitudinal axis into parallel slices of approximately 1 mm
thickness, with the first cut positioned randomly within an interval
of 1 mm length at the splenic end of the pancreas. Slices were
placed in tissue capsules on a piece of foam-rubber sponge with the
right cut surface facing downward. Then embedding in paraffin
(every first slice) and plastic (GMA/MMA; every second slice) was
performed. The morphological changes of the endocrine pancreas
were evaluated quantitatively applying unbiased model-indepen-
dent stereological methods [15] as described [12,14].
Total volumes of islets, beta-cells, and isolated beta-cells
Total volumes of islets, beta-cells and isolated beta-cells - an
indicator for islet neogenesis [16,17] - were determined essentially
as described previously [14], using the following equations:
1) Pancreas volume:
VPan = Pancreas weight/specific weight of mouse pancreas
(1.08 mg/mm3)
2) Total islet volume:
V(Islets,Pan) = gAislets/gApancreas x VPan
3) Total beta-cell volume:
V(B-cells,islets) = gAB-cells/gAislets x V(Islets,Pan)
4) Total volume of isolated beta-cells:
V(Neo,Pan) = gAisolated beta-cells/gApancreas x VPan
gA equals the sum of cross-sectional areas of the respective
compartment.
An example of anti-insulin stained islet profiles of a control and
a transgenic mouse is shown in Fig. 1 A and B.
Determination of number and size of islets and beta-cells
Total islet and total beta-cell numbers were determined using
plastic sections, applying the disector method [18]. The physical
disector, which consists of a pair of physical section planes
separated by a known distance, was used to estimate the numerical
density of islets in the pancreas and of beta-cells in the islets. The
distance between both sections (disector height) was chosen to be
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approximately 30% of the mean minimum diameter of the objects
to be counted [19], and accounted for 18 mm and 1.5 mm for islets
and beta-cells, respectively. The mean minimum diameter of islets
and beta-cells was determined planimetrically. The plastic
embedded pancreas was cut exhaustively into 1.5 mm thick
sections, and the primary sections for counting islets were sampled
beginning at a random start between the first and 12th section, the
corresponding reference section was sampled 12 sections ahead
(Fig. 1C). All sampled sections for determination of islet numbers
were stained with H&E. For counting Q2 beta-cells, three series of
adjacent sections were selected from the sections not used for
H&E-staining. The primary section was chosen, beginning at a
random start between section 2 and 11, the reference section was
drawn one section ahead (Fig. 1C). These selected plastic sections
were stained immunohistochemically for insulin.
A particle (Q2) is counted when it is present in the primary but
not in the reference section. The process of counting Q2 was then
repeated by interchanging the roles of the primary and reference
section, thereby increasing the efficiency by a factor of two.
Q2 islets were counted, using two microscopes (final magnifi-
cation 100x). Clusters of endocrine cells were only regarded as
islets when at least five nuclear profiles were visible. A section pair
for counting Q2 islets is illustrated in Fig. 1D/E. Following
equations were used for calculations:
Figure 1. Representative islet profiles, sampling of sections, counting Q2 islets. Example of an islet profile of a control (A) and a GIPRdn
transgenic mouse (B) immunohistochemically stained for insulin; (C) Sampling scheme for drawing primary and reference sections; (D) Primary
section and (E) reference section for counting Q2 islets, one Q2 may be counted in the example (arrow in E).
doi:10.1371/journal.pone.0022814.g001
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1) Numerical volume density of islets in the pancreas:
Nv(Islets/Pan) = Q
2/(gApancreas x h) x fs
3
2) Number of islets in the pancreas
N(Islets,Pan) = Nv(Islets/Pan) x V(Pan)
3) Mean islet volume
v(Islets) = gAislets/gApancreas / Nv(Islets/Pan)
h: disector height (18 mm), fs: linear tissue shrinkage factor
(0.9160.02); on the average 40 Q2 were counted per animal.
For counting Q2 beta-cells, immunohistochemically stained
sections were used: with a random start within the first slice of
pancreas of the primary section, islets in every second strip were
sampled until a total number of five islets in wild-type mice and
seven islets in transgenic mice was reached. Photographs of the
selected islets and the corresponding islets in the reference section
were taken, and printed at a final magnification of 1530x. A plastic
transparency with an unbiased counting frame was applied to the
print-outs, and the Q2 beta-cells were counted according to the
unbiased counting rule [18]. The area of the counting frame
corresponds to the disector area (gAdisector). In case of small islets
which were smaller than the counting frame, the whole islet area
was used as disector area.
The following equations were used for calculations:
4) Numerical volume density of beta-cells in islets
Nv(B-cells/Islets) = Q
2/(gAdisector x h) x fs
3
5) Total number of beta-cells in the islets
N(B-cells,Islets) = Nv(B-cells/Islets) x V(B-cells, Islets).
6) Mean beta-cell volume
v(B-cells) = gAB-cells/gAislets / Nv(B-cells/Islets).
h: disector height (1.5 mm), fs: linear tissue shrinkage factor
(0.9160.02); On the average, 47 Q2 were counted per animal.
Islet-cell replication and apoptosis
BrdU and TUNEL positive nuclear profiles of islet-cells were
counted, using immunohistochemically stained paraffin sections.
With a random start within a section of the first slice of
pancreas, the whole slide was surveyed by meandering, neglecting
every second strip. At 10 days of age, all islet profiles were
analyzed. Stained and un-stained nuclear profiles of islet-cells
were counted and the areas of the corresponding islets were
measured planimetrically. The total number of islet cell nuclei
was obtained as the product of the numerical area density of islet
cell nuclei and the islet area. The numbers of BrdU and TUNEL
positive nuclear profiles are stated as number of positive cells per
100,000 nuclei.
Statistical analyses
Statistical analyses of all data but insulin tolerance tests were
performed, using one-way analysis of variance (ANOVA),
differences between genetic groups and age-groups were deter-
mined by pair wise comparisons, using the LSD test, with P,0.05
indicating statistical significance (IBM SPSS Statistics 19.0, IBM
Deutschland GmbH, Germany). Data from insulin tolerance tests
were compared by Mann Whitney U-test. Quantitative stereolog-
ical data were logarithmically transformed to approximate normal
distribution. Data are presented as means and standard error of
means (SEM) throughout the study.
Results
Postnatal development of islets and beta-cells in healthy
CD1 mice
The total islet and beta-cell volumes more than tripled in
healthy control mice between 10 and 90 days of age and remained
stable thereafter (Fig. 2A, B). This increase in islet and beta-cell
mass was associated with a two-fold increase in islet number at 90
vs. 10 days of age and islet number was 2.6-fold higher at 180 vs.
10 days of age (Fig. 2C). The mean islet volume of controls did not
change significantly in the period investigated (Fig. 2D). The total
number of beta-cells in the pancreas was 7-times higher at 180
days vs. 10 days of age (Fig. 2E), whereas the mean beta-cell
volume decreased significantly between 10 and 45 days of age (by
39%) and remained stable thereafter (Fig. 2F).
The increase in both total islet and beta-cell volumes and
numbers was associated with high islet-cell replication and
neogenesis of islets at 10 days of age. Islet-cell replication declined
between 10 and 45 days of age, and was undetectable in 180-day-
old control females (Fig. 3A). The total volume of isolated beta-
cells, an indicator for islet neogenesis [16,17], declined significantly
between 10 and 45 days of age, and remained at low levels
thereafter (Fig. 3B). Low levels of islet-cell apoptosis were
detectable at 10 and 45 days of age, no apoptosis was
demonstrable in controls thereafter (Fig. 3C).
Impaired glucose tolerance, reduced insulin levels,
oxidative stress and insulin resistance in GIPRdn
transgenic mice
At ten days of age, there was no difference in blood glucose or
serum insulin levels between transgenic and control mice. At 45,
90 and 180 days of age, fasting blood glucose levels were
significantly higher in transgenic mice (Fig. 4A) and serum insulin
levels were about 50% lower in transgenic mice vs. controls
(Fig. 4B). Serum malondialdehyde (MDA) levels were comparable
in 45-day-old mice, and were significantly increased in 90- and
180-day-old GIPRdn transgenic mice vs. controls (Table 1).
Glucose disposal in response to exogenous insulin was
significantly reduced in transgenic mice, 10, 20 and 30 minutes
after insulin administration (Fig. 4C), and the area under glucose
curve was significantly higher in GIPRdn transgenic mice vs.
controls (Fig. 4D).
Preserved incretin effect on insulin secretion in
10-day-old GIPRdn transgenic mice
Glucose administration alone or with GIP or GLP-1 lead to a
significant increase in blood glucose levels vs. basal levels in all
animals investigated (Fig. 5A). GIPRdn transgenic mice showed a
significantly lower (,70%) pancreatic insulin content vs. controls
(24396641 ng/ml vs. 802762306 ng/ml), and serum insulin
levels after stimulation with glucose, GLP-1 and GIP were
significantly lower than those of control mice, whereas basal and
arginine stimulated insulin levels did not differ from controls
(Fig. 5B). In controls, GIP- and GLP-1-stimulated serum insulin
levels were significantly higher, arginine stimulated insulin levels
were by trend higher (p = 0.062) than basal levels. In transgenic
mice, GLP-1-stimulated insulin concentrations were also signifi-
cantly higher than basal levels (Fig 5B). However, there were no
differences in serum insulin relative to basal levels (fold insulin
secretion) comparing GIPRdn transgenic and control mice,
irrespective of the secretagogue applied (Fig. 5C). In addition,
the serum insulin to pancreatic insulin ratio (relative secretion) was
significantly higher following GIP, GLP-1 and arginine stimulation
vs. basal ratio in control mice. In transgenic mice, relative
secretion following GLP-1 and arginine was significantly higher,
and following GIP stimulations was by trend higher (p = 0.07) than
basal ratios. GLP-1 and arginine induced serum insulin to
pancreatic insulin ratios were significantly higher in transgenic
mice vs. controls (Fig 5D).
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Postnatal development of islets and beta-cells of GIPRdn
transgenic mice
Transgenic mice exhibited significantly lower total islet and
beta-cell volumes than control mice, irrespective of the age at
sampling (Fig. 2A, B). Accordingly, the total numbers of islets and
beta-cells were significantly lower in transgenic mice at all time
points investigated (Fig. 2C, E). The mean islet and beta-cell
volumes were equal in transgenic and control mice at 10 and 45
days of age, but were significantly smaller at 90 and 180 days of
age in transgenic mice vs. controls (Fig. 2D, F). In contrast to
controls, total beta-cell volumes and numbers decreased signifi-
cantly between 45 and 90 days of age (Fig. 2B, E), however, the
number of islets almost doubled in adult GIPRdn transgenic mice
between 45 and 90 days (p,0.05, Fig. 2C). Consequently, the
mean islet volume initially increased but dropped by ,70%
between 45 and 90 days of age (Fig. 2D). Like in controls, the
mean beta-cell volume of transgenic mice decreased significantly
between 10 and 45 days of age, and remained stable thereafter
(Fig. 2F).
The amount of replicating islet-cells was comparable to control
mice at 10 days, and was 3-fold higher vs. controls at 45 days. At
90 days of age, no replicating islet cells were observed in GIPRdn
transgenic mice, which is in contrast to controls (Fig. 3A). The lack
of islet and beta-cell mass expansion of transgenic mice was
associated with significantly disturbed islet neogenesis vs. controls
(Fig. 3B). The frequency of apoptotic islet-cells appeared slightly
higher in 10- and 45-day-old transgenic mice and was significantly
higher at 90 days vs. controls. At 180 days of age, no apoptotic islet
cells were evident in transgenic and control mice (Fig. 3C).
cAMP in isolated islets
The cAMP content in isolated islet of 10-day-old control and
GIPRdn transgenic mice did not differ (0.0960.02 pmol/islet vs.
0.1060.02 pmol/islet).
Discussion
The knowledge of postnatal development of the islets of
Langerhans is a crucial prerequisite for the interpretation of the
Figure 2. Quantitative-stereological investigations of the endocrine pancreas. (A) Total islet volume (V(Islets,Pan), (B) total beta-cell volume
(V(B-cells,Islets), (C) Number of islets (N(Islets, Pan), (D) mean islet volume (v(islets), (E) beta-cell number (N(B-cells,Islets), (F) mean beta-cell volume (v(B-cells).
Open bars: female control mice; filled bars: female GIPRdn transgenic mice; Data represent means and SEM. * p,0.05 vs. age-matched control;
+p,0.05 vs. previous time point.
doi:10.1371/journal.pone.0022814.g002
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changes occurring in diabetes and may have an important impact
on the development of new therapeutic strategies, addressing
expansion of beta-cell mass. Rodent models are primarily used to
address the efficacy and safety of novel therapies in preclinical
studies. Several excellent studies on mechanisms of postnatal islet
and beta-cell growth have been published in the past, including
studies addressing islet- and beta-cell mass expansion and different
lineage-tracing studies [1,20,21]. Detailed analyses of the age-
related development of the numbers and mean volumes of islets
and beta-cells have been performed in rats, investigations in mice
however are scarce [22,23,24]. Therefore, we chose to investigate
postnatal development of the endocrine pancreas in mice, using
state-of-the-art stereological methods [12,14,15,25,26].
Age-related changes in islet and beta-cell mass of CD1
mice
In healthy CD1 mice, both islet and beta-cell mass increased
significantly until 90 days of age and stayed constant thereafter.
These findings are in line with our previous analyses and obser-
vations in other studies on rodents [12,22,27,28]. Similar changes
were suggested to occur in humans, since the stimulated C-peptide
response increases from childhood to adolescence in individuals at
risk for type 1 diabetes mellitus [13]. It was shown that beta-cell
mass in non-diabetic humans also increases with age, the largest
growth rates being observed within the first six years of life [29].
We could show in the present study that the early expansion of
total islet and beta-cell volumes of control mice was associated with
a high rate of both islet-cell replication and neogenesis of islets.
The observed high replication rate supports the concept that
postnatal expansion of islet or beta-cell mass is due to replication of
existing islet-cells, rather than neogenesis from precursors or stem
cells [2,4,30,31]. However, neogenesis has recently been shown to
play an important role in regeneration of the endocrine pancreas
after partial duct ligation [32].
High replication rates of islet-cells were reported between one
and two, and between three and four months of age in rodents, the
time course when total beta-cell mass doubled in healthy rodents.
Thereafter, replication of islet cells was rather slow and the rate of
replication reached that of apoptosis (2–3% per day), leading to a
stable beta-cell mass [27]. In humans, a wave of beta-cell apoptosis
occurs perinatally [33], replication rates are highest at gestation
and in young children under about 6 months of age, and decline to
low levels thereafter [29,33].
Age-related changes in islet and beta-cell size and
number of CD1 mice
The present study shows that the postnatal increase of islet and
beta-cell mass of healthy female CD1 mice is associated with a
pronounced increase in number of islets and beta-cells (i.e.
hyperplasia of islets and beta-cells), whereas the mean islet size
does not change (no islet hypertrophy). Further, the mean beta-cell
size decreased significantly between 10 and 45 days of age in
control mice. The above findings are in contrast to some other
observations in rodents, which have suggested that the islet
number is fixed in the early postnatal period, and that the growth
of the endocrine pancreas is due to islet hypertrophy [1,2,3,4,34].
The same conclusion was made in a recent study from humans
[29]. However, in one study, examining the postnatal development
of islet number and size in the rat, using unbiased model-
independent quantitative-stereological techniques, the authors
show that islet number increases significantly with age, while the
mean size of the islets even decreases [23]. In male BALB/c mice
between 1 week and 10 months of age, islet numbers were recently
quantified after collagenase digestion of the pancreas, showing that
the number of islets that may be harvested, increased largely in the
first two months of life and stayed stable thereafter [24]. We
showed that islet number increases significantly up to 3 months of
age in female CD1 control mice, and a trend of a further increase
in islet number up to 6 months was observed. Another study in rats
showed that the mean beta-cell profile area does not change in rats
from 2 to 31 days of age, whereas the beta-cell number triples
[1,22]. Likewise, another report demonstrated that mean beta-cell
Figure 3. Islet-cell replication, isolated beta-cells, and islet-cell
apoptosis. (A) number of BrdU positive islet cells per 105 cells (N(BrdU)),
(B) total volume of isolated beta-cells (V(Neo,Pan), (C) number of
apoptotic islet cells per 105 cells (N(Apoptosis)). Open bars: female control
mice; filled bars: female GIPRdn transgenic mice; Data represent means
and SEM. * p,0.05 vs. age-matched control; +p,0.05 vs. previous time
point.
doi:10.1371/journal.pone.0022814.g003
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volumes of rats remained constant from 21 days of age, onwards
[27]. These differences to our investigations in CD1 mice could be
strain and gender specific or result from different methodologies
used for analyzing islet and beta-cell size and number.
In spite of high islet-cell replication and a low rate of apoptosis,
mean islet size did not change with age in female CD1 mice
examined in the present study. Therefore, fission of islets might
contribute to the increase in islet number. It has been suggested
that fission of islets, or budding of new islets from existing ones,
occurs in mice and rats, in order to keep an optimal islet size
[2,6,16,23]. Another explanation for a constant mean islet size of
female CD1 controls could be the neonatal wave of apoptosis,
which is thought to be highest in the first weeks of life when a
remodeling of the endocrine pancreas takes place [22]. In the
present study we could not demonstrate higher levels of apoptosis
in sibling CD1 mice as compared to mice after weaning, however,
since morphological signs of apoptosis are short-lived, and
apoptotic cells are rapidly cleared by macrophages, the exact rate
of islet-cell apoptosis is difficult to determine [28,35,36]. In
addition, quantification of islet-cell apoptosis in histological
sections only gives a snapshot of the situation and not a long-
term read out. However, different methodologies used for
visualization of apoptotic cells may also account the discrepancies
between our results and other investigations.
Glucose homeostasis of GIPRdn transgenic female mice
GIPRdn transgenic mice investigated in the present study
exhibited a diabetic phenotype after weaning, characterized by
fasting hyperglycemia and hypoinsulinemia, which is in line with
our previous investigations [12,37]. Serum malondialdehyde levels
were determined as marker for oxidative stress. GIPRdn transgenic
mice exhibited significantly increased serum malondialdehyde
levels from 90 days of age onwards, indicating oxidative stress due
to chronic hyperglycemia.
It was previously shown that insulin secretion following a
glucose challenge was largely reduced in diabetic GIPRdn
transgenic mice and could not be augmented by administration
of GLP-1, suggesting the loss of functional beta-cell mass and/or
non-specific effects of transgene expression [12]. In the present
study, insulin secretion following stimulation with glucose, glucose
with GIP or GLP-1 and arginine was determined before the onset
of hyperglycemia in 10-day-old animals. There were no significant
Figure 4. In vivo investigations. (A) Randomly fed (10 days) and fasting blood glucose (45-180 days), and (B) randomly fed (10 days) and
postprandial serum insulin levels (45–90 days), (C) insulin tolerance test, (D), and area under glucose curve (AUC) during insulin tolerance test shown
in C; co, control; tg, GIPRdn transgenic; Data represent means and SEM, * p,0.05 vs. age-matched control.
doi:10.1371/journal.pone.0022814.g004
Table 1. Lipid peroxidation.
MDA (mmol/l)
45 d 90 d++ 180 d++
Co 48618 40611++ 4166++
Tg 3569 79612*+ 296624*+
Serum malondialdehyde (MDA) levels of GIPRdn transgenic (tg) and control (co)
mice at 45, 90 and 180 days of age. Data represent means and SEM;
*p,0.05 vs. age-matched control;
+ p,0.05 vs. previous time point.
doi:10.1371/journal.pone.0022814.t001
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differences in basal and arginine stimulated serum insulin levels
comparing transgenic and control mice. In GIPRdn transgenic
mice, glucose, GIP and GLP-1 stimulated insulin levels were
significantly lower than those of control mice; however, since the
pancreatic insulin content and beta-cell numbers were already
reduced by 70% in transgenic animals, the reduced serum insulin
levels may be a consequence of reduced beta-cell mass, rather than
due to a secretion defect. The increase of insulin levels from basal
(Fig. 5C) did not differ between the genetic groups, irrespective of
the secretagogue applied, arguing against non-specific secretion
defects due to e.g. recruiting of intracellular signaling molecules by
overexpression of the dominant negative receptor. In addition, the
serum insulin to pancreatic insulin ratio was calculated, showing
that the remaining beta-cells of GIPRdn transgenic mice respond
normally to pharmacological doses of GIP. This is in line with data
obtained from 11-week-old GIPRdn transgenic pigs 10 minutes
after application of glucose and GIP [38]. In contrast to mice
lacking the GIPR that do not respond to GIP, GIPRdn transgenic
mice and pigs exhibit functional endogenous GIP receptors that
compete with the GIPRdn for the ligand GIP, explaining why
GIPRdn transgenic animals may respond to GIP stimulation.
GIPRdn transgenic mice even show two-fold higher serum insulin
to pancreatic insulin ratios vs. control mice following GLP-1 or
arginine stimulation. Likewise, GIPR-/- mice showed an upregula-
tion of the GLP-1 component of the enteroinsular axis [39], and
GIPRdn transgenic pigs showed increased responsiveness to
exendin-4 [40]. Studies in GIPR and GLP-1R knockout mice
demonstrated increased cAMP levels following GLP-1 or GIP
stimulation, respectively. Unfortunately, isolated islets of GIPRdn
transgenic mice are too fragile to use them for in vitro stimulation
assays and do not survive over night recovery after isolation
procedure, therefore we could only determine basal cAMP in islets
right after isolation, which did not differ between the genetic
groups. Likewise, basal cAMP was not different comparing
GIPR-/- and wild-type mice [41]. Taken together, the results
from the in vivo secretion studies argue against non-specific effects
of transgene overexpression on insulin secretion.
In addition we have shown in the present study that, GIPRdn
transgenic mice exhibit slight insulin resistance. Insulin resistance
has been observed in other mouse models with insulin deficient
diabetes [14] and results from chronically elevated blood glucose
levels [42], and reduced fat and muscular tissue [37].
Age-related changes of the endocrine pancreas in female
GIPRdn transgenic mice
In female GIPRdn transgenic mice analyzed in the present
study, total volumes as well as absolute numbers of islets and beta-
cells were significantly reduced vs. age-matched control mice
Figure 5. In vivo insulin secretion studies at 10 days of age. (A) Blood glucose, (B) serum insulin levels, (C) increase of serum insulin levels from
basal levels (fold insulin secretion), (D) serum insulin to pancreatic insulin ratio; Open bars: control mice; filled bars: GIPRdn transgenic mice; Data
represent means and SEM. * p,0.05 vs. age-matched control; + p,0.05 vs. basal values.
doi:10.1371/journal.pone.0022814.g005
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(hypoplasia of islets and beta-cells). In human type 2 diabetic
patients, conflicting data exist about beta-cell mass. Several studies
reported a decreased total volume or volume density of beta-cells
in the pancreas of diabetic patients [41,43], whereas others did not
observe a reduction in beta-cell mass [44,45]. Mean beta-cell
volumes and beta-cell numbers of GLP-1R deficient mice were
comparable to wild-type mice [46,47]. Beta-cell mass was also
unaltered in Glp1r knockout mice as compared to wild-type mice,
however, islet regeneration following partial pancreatectomy was
largely disturbed in Glp1r knockout mice [47]. In Gipr-/- mice,
beta-cell area as a percentage of total pancreatic area (i.e. volume
density of beta-cells in the pancreas) was significantly increased in
knockout vs. wild-type mice. However, the staining intensity for
insulin was reduced in Gipr-/- islets, and the pancreatic insulin
content was significantly lower [39]. In double incretin receptor
knockout mice, the beta-cell to pancreas area-ratio was also
unaltered vs. wild-type mice [48]. The difference in the pancreatic
phenotype of GIPRdn transgenic mice vs. the knockout models
could be explained by yet undefined compensatory mechanisms of
incretin receptor knockout models that are not triggered in
GIPRdn transgenic mice (or pigs, [38]), that harbor functional
endogenous GIP receptors. Therefore we hypothesize that early
disruption of GIPR-signaling, induced by a competition of the
mutated and the endogenous wild-type receptor for the ligand GIP
[12], primarily induces a disturbance in the expansion of the
endocrine pancreas. However, it cannot be completely excluded
that the mutant GIP receptor might recruit intracellular G-
proteins, leading to reduced signaling of other G-protein coupled
receptors of the beta-cells (GLP-1, glucagon receptor). To our
knowledge, GIPR mutations have only been investigated in type 2
diabetic patients but not in patients exhibiting neonatal or
maturity onset diabetes mellitus of unknown cause. Taking the
changes in beta-cell mass of GIPRdn transgenic mice and pigs [38]
into account, screening for GIPR mutations in human subjects
other than type 2 diabetics may be indicated.
Islet neogenesis, as evaluated by the total volume of isolated
beta-cells, was severely reduced in GIPRdn transgenic mice vs.
controls, which is in line with our previous investigations [12], and
islet-cell replication was significantly lower vs. controls, implying
disturbed development of the endocrine pancreas due to a
decrease in replication of existing beta-cells and reduced
neogenesis from endocrine progenitors [40,49]. GIP is known to
influence beta-cell apoptosis and survival via cAMP-dependent
modulation of ERK1/2 and p38MAPK [9,50]. Islet-cell apoptosis
in pancreas sections was only by trend increased in 10-day-old
controls and GIPRdn transgenic mice. Therefore, disturbed islet
neogenesis initially appears to mainly account for the reduction in
beta-cell mass of GIPRdn transgenic mice, arguing against massive
toxic effects of transgene expression on islet-cell survival [51].
However, since both GIP and GLP-1 are known to exert
proliferative, and anti-apoptotic effects on beta-cells in vitro, and
in vivo [52,53], an increased frequency of apoptotic islet-cells would
be expected in GIPRdn transgenic mice. Apoptotic cells are rapidly
cleared by macrophages therefore, the determination of the exact
frequency of apoptotic cells in histological sections is difficult and
may lead to the large variation in this parameter.
During postnatal pancreas development, the number of islets
increased significantly between 45 and 90 days of age in GIPRdn
transgenic mice. The total volume of isolated beta-cells was highest
in 10-day-old transgenic mice and significantly declined thereafter.
Therefore, islet neogenesis does not appear to be completely
abolished in GIPRdn transgenic mice. However, the ,2-fold
increase in islet number suggests that fission of islets occurs, similar
to controls [6,23]. Unlike in controls, the mean islet size initially
increased in transgenic mice. Therefore, high replication would be
expected, in order to increase islet size, and actually we
demonstrate here that the mean frequency of replicating islet-
cells was three-times that of controls at 45 days of age. The
expansion of beta-cell mass in response to glucose is generally
believed to be associated with an increase of not only beta-cell
number but also mean size of beta-cells [35,54,55,56,57].
Therefore we suggest that acute/sub-acute hyperglycemia could
account for the high frequency of replicating islet-cells observed in
GIPRdn transgenic mice at 45 days of age [58,59].
In contrast to the younger age-groups, apoptosis was signif-
icantly increased and islet-cell replication was lacking in transgenic
mice vs. controls at 90 days, resulting in a significant decline of the
total beta-cell volume, beta-cell number, and mean islet size with
age. The observations of the present study imply progressive beta-
cell loss occurring around 90 days of age, due to chronic
hyperglycemia (glucotoxicity) [2,59]. Serum malondialdehyde
levels, a marker for oxidative stress, were significantly increased
in transgenic mice from 90 days of age onwards vs. controls,
supporting the hypothesis of beta-cell loss due to glucotoxicity.
Glucose has been reported to have an ambiguous effect on beta-
cell mass. Glucose in limited concentrations administered for a
short period of time leads to an increase in beta-cell mass, while
excessive amounts of glucose over a prolonged period exert
negative effects on beta-cell function and also may negatively affect
beta-cell mass by inducing apoptosis [59]. Beta-cell hypertrophy is
reported in studies using glucose infusions to stimulate expansion
of beta-cell mass of non-diabetic and mildly diabetic rats [60].
Beta-cell hypertrophy may also contribute to the increase in beta-
cell mass as a means of adaptation to an increased insulin demand
due to insulin resistance in diabetic subjects [61,62]. In contrast,
GIPRdn transgenic mice investigated in the present study not only
show reduced numbers, but also reduced mean volumes of beta-
cells. Similarly, no compensatory beta-cell hypertrophy was
observed in type 2 diabetic patients despite chronic exposure to
high glucose levels [63].
In summary, we could show that physiological postnatal growth
processes of the endocrine pancreas of female CD1 mice involve
islet and beta-cell hyperplasia, but no considerable islet or beta-cell
hypertrophy. Replication of islet-cells, neogenesis and fission of
islets were demonstrated to contribute to postnatal expansion of
the murine endocrine pancreas. GIPRdn transgenic mice exhibit
disturbed islet neogenesis, but fission of islets, and islet-cell
apoptosis are initially unaltered. The resulting early reduction in
beta-cell number leads to the severe diabetic phenotype of GIPRdn
transgenic mice after weaning, with a further age-related decline of
beta-cell numbers, the latter being most likely attributable to
oxidative stress.
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